Tech Company Financing Transactions
Ceptur Therapeutics Funding Round
Ceptur Therapeutics, based in Hillsborough, secured $75 million from Qiming Ventures, venBio and Affinity Asset Advisors.
Transaction Overview
Company Name
Announced On
1/28/2022
Transaction Type
Venture Equity
Amount
$75,000,000
Round
Series A
Investors
Qiming Ventures (Lead Investor)
venBio (Lead Investor) (Aaron Royston)
Proceeds Purpose
The funds raised from the Series A will be used for platform optimization, advance the Discovery pipeline, and expand operations in Philadelphia and Copenhagen.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Ilene Ct., Bldg. 8 9
Hillsborough, NJ 08844
USA
Hillsborough, NJ 08844
USA
Phone
Website
Email Address
Overview
Ceptur is developing unique and differentiated genetic medicines for patients with unaddressed diseases, using its wholly owned and proprietary U1 Adaptor technology.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Peter Ghoroghchian
Chief Financial Officer
Keith Dewedoff
Chief Technical Officer
Christoph Rosenbohm
Co-Founder
Rafal Goraczniak
Vice President
Myung Shin
Browse more venture capital transactions:
Prev: 1/28/2022: Radian Aerospace venture capital transaction
Next: 1/29/2022: Mention Me venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here are derived from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs